Item 7.01. Regulation FD Disclosure.

The Company announced on January 10, 2022, the signing of a feasibility agreement with Kindeva Drug Delivery to develop Nutriband's lead product, AVERSA™ Fentanyl, based on its proprietary AVERSA™ abuse deterrent transdermal technology and Kindeva's FDA-approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement is focused on adapting Kindeva's commercial transdermal manufacturing process to incorporate AVERSA technology.

See Press Release attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits





(d) Exhibits

The following exhibits are being filed with this Current Report on Form 8-K:





99.1        Nutriband Press Release dated January 10, 2022.
104       Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       1

© Edgar Online, source Glimpses